Otonomy (OTIC) Says Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus Demonstrated No Clinically Meaningful Benefit Versus Placebo

Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus

OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepointsCompany to discontinue development of OTO-313 and implement other measures to extend its cash runway Clinical focus shifts to OTO-413 following positive Phase 2a results in April 2022; top-line results for evaluation of higher dosing still expected in fourth quarter of 2022

SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the OTO-313 Phase... More